**Hemovigilance Module**

**Monthly Reporting Denominators**

**\*Required for saving**

|  |  |  |
| --- | --- | --- |
| \*Facility ID#: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \*Month: \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \*Year: \_\_\_\_\_\_\_\_\_\_\_\_ |
| **Table 1** |
| **Products** | **\*Units Transfused** | **\*Aliquots Transfused** | **\*Total Discards** |
| Whole Blood | **TOTAL** |  |  |  |
| Red blood cells | Whole blood derived  | **TOTAL** |  |  |  |
| Not irradiated or leukocyte reduced |  |  |  |
| Irradiated |  |  |  |
| Leukocyte reduced |  |  |  |
| Irradiated and leukocyte reduced |  |  |  |
| Apheresis | **TOTAL** |  |  |  |
| Not irradiated or leukocyte reduced |  |  |  |
| Irradiated |  |  |  |
| Leukocyte reduced |  |  |  |
| Irradiated and leukocyte reduced |  |  |  |
| Platelets | Whole blood derived | **TOTAL** |  |  |  |
| Not irradiated or leukocyte reduced |  |  |  |
| Irradiated |  |  |  |
| Leukocyte reduced |  |  |  |
| Irradiated and leukocyte reduced |  |  |  |
| Apheresis | **TOTAL** |  |  |  |
| Not irradiated or leukocyte reduced |  |  |  |
| Irradiated |  |  |  |
| Leukocyte reduced |  |  |  |
| Irradiated and leukocyte reduced |  |  |  |
| Plasma(all types) | Total whole blood derived |  |  |  |
| Total apheresis |  |  |  |
| Cryoprecipitate |  |  |  |

**Hemovigilance Module**

**Monthly Reporting Denominators**

|  |
| --- |
| \*Does your facility transfuse blood products treated with pathogen reduction technology? \_\_\_\_\_ Yes \_\_\_\_\_\_\_ No^If yes, then complete Table 2. **Table 2** |
|

|  |  |  |  |
| --- | --- | --- | --- |
| **Products** | **Units Transfused** | **Aliquots Transfused** | **Total Discards** |
| Red blood cells | Whole blood derived |  TOTAL |  |  |  |
| S-303-treated |  |  |  |
| Riboflavin-treated |  |  |  |
| Apheresis | TOTAL |  |  |  |
| S-303 -treated |  |  |  |
| Riboflavin-treated  |  |  |  |
| Platelets | Whole blood derived  | TOTAL |  |  |  |
| Psoralen-treated |  |  |  |
| Riboflavin-treated |  |  |  |
| Apheresis  | TOTAL |  |  |  |
| Psoralen-treated |  |  |  |
| Riboflavin-treated |  |  |  |
| Plasma(all types) | Whole blood derived  | TOTAL |  |  |  |
| Psoralen-treated |  |  |  |
| Riboflavin-treated |  |  |  |
| Apheresis  | TOTAL |  |  |  |
| Psoralen-treated |  |  |  |
| Riboflavin-treated |  |  |  |
| Cryoprecipitate | TOTAL |  |  |  |
| Psoralen-treated |  |  |  |
| Riboflavin-treated |  |  |  |
| Pathogen Reduction Cryoprecipitated Fibrinogen Complex |  |  |  |

^If your facility transfused pathogen reduced apheresis platelets (e.g., the apheresis platelet total in table 2 is greater than 0), then complete Table 3.**Table 3**

|  |  |  |  |
| --- | --- | --- | --- |
| **Products** | **Units Transfused** | **Aliquots Transfused** | **Total Discards** |
| Platelets | Apheresis  | Psoralen-treated |  |  |  |
| Psoralen-treated and in Plasma |  |  |  |
| Psoralen-treated and in Platelet additive solution |  |  |  |
| Riboflavin-treated |  |  |  |
| Riboflavin-treated and in Plasma |  |  |  |
| Riboflavin-treated and in Platelet additive solution |  |  |  |

\*Patient samples collected for type and screen or crossmatch: \_\_\_\_\_\_\_\_\_\_ |
| \*Total crossmatch procedures: \_\_\_\_\_\_\_\_\_\_ |
| Total patients transfused: \_\_\_\_\_\_\_\_\_\_ |

**Hemovigilance Module**

**Monthly Reporting Denominators**

|  |
| --- |
| **Custom Fields** |
| Label |  | Label |  |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  |  |  |  |